REFERENCES
1. Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA. 2022;327:662-75.
2. Park DW, Clare RM, Schulte PJ, et al. Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA. 2014;312:2019-27.
3. Balbi MM, Scarparo P, Tovar MN, et al. Culprit lesion detection in patients presenting with non-ST elevation acute coronary syndrome and multivessel disease. Cardiovasc Revasc Med. 2022;35:110-8.
4. Sorajja P, Gersh BJ, Cox DA, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J. 2007;28:1709-16.
5. Mehta SR, Wood DA, Storey RF, et al. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2019;381:1411-21.
6. Tonino PA, Fearon WF, De Bruyne B, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol. 2010;55:2816-21.
7. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45:3415-537.
8. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44:3720-826.
9. Fabris E, Kedhi E, Verdoia M, et al. Current role of intracoronary imaging for implementing risk stratification and tailoring culprit lesion treatment: a narrative review. J Clin Med. 2023;12:3393.
10. Ganzorig N, Pompei G, Jenkins K, et al. Role of physiology in the management of multivessel disease among patients with acute coronary syndrome. AsiaIntervention. 2024;10:157-68.
11. Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213-24.
12. De Bruyne B, Pijls NH, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991-1001.
13. Zimmermann FM, Omerovic E, Fournier S, et al. Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data. Eur Heart J. 2019;40:180-6.
14. Smits PC, Laforgia PL, Abdel-Wahab M, et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction: three-year follow-up with cost benefit analysis of the Compare-Acute trial. EuroIntervention. 2020;16:225-32.
15. Engstrøm T, Kelbæk H, Helqvist S, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3 - PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015;386:665-71.
16. Böhm F, Mogensen B, Engstrøm T, et al. FFR-Guided Complete or Culprit-Only PCI in patients with myocardial infarction. N Engl J Med. 2024;390:1481-92.
17. Sels JW, Tonino PA, Siebert U, et al. Fractional flow reserve in unstable angina and non-ST-segment elevation myocardial infarction experience from the FAME (Fractional flow reserve versus Angiography for Multivessel Evaluation) study. JACC Cardiovasc Interv. 2011;4:1183-9.
18. Layland J, Oldroyd KG, Curzen N, et al. Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. Eur Heart J. 2015;36:100-11.
19. Puymirat E, Cayla G, Simon T, et al. Multivessel PCI guided by FFR or angiography for myocardial infarction. N Engl J Med. 2021;385:297-308.
20. Puymirat E, Cayla G, Simon T, et al. Three-year outcomes with fractional flow reserve-guided or angiography-guided multivessel percutaneous coronary intervention for myocardial infarction. Circ Cardiovasc Interv. 2024;17:e013913.
21. Lee JM, Kim HK, Park KH, et al. Fractional flow reserve versus angiography-guided strategy in acute myocardial infarction with multivessel disease: a randomized trial. Eur Heart J. 2023;44:473-84.
22. Elbadawi A, Dang AT, Hamed M, et al. FFR- versus angiography-guided revascularization for nonculprit stenosis in STEMI and multivessel disease: a network meta-analysis. JACC Cardiovasc Interv. 2022;15:656-66.
23. Omar A, Senguttuvan NB, Ueyama H, et al. Meta-analysis comparing fractional flow reserve and angiography-guided complete revascularization of nonculprit artery for ST-elevation myocardial infarction. Am J Cardiol. 2022;183:8-15.
24. Musto C, De Felice F, Rigattieri S, et al. Instantaneous wave-free ratio and fractional flow reserve for the assessment of nonculprit lesions during the index procedure in patients with ST-segment elevation myocardial infarction: the WAVE study. Am Heart J. 2017;193:63-9.
25. van der Hoeven NW, Janssens GN, de Waard GA, et al. Temporal changes in coronary hyperemic and resting hemodynamic indices in nonculprit vessels of patients with ST-segment elevation myocardial infarction. JAMA Cardiol. 2019;4:736-44.
26. Vikhert AM, Cherpachenko NM. Changes in metabolism of undamaged sections of myocardium following infarction. Circ Res. 1974;35:182-91.
27. Ntalianis A, Sels JW, Davidavicius G, et al. Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. JACC Cardiovasc Interv. 2010;3:1274-81.
28. Legutko J, Bryniarski KL, Kaluza GL, et al. Intracoronary imaging of vulnerable plaque-from clinical research to everyday practice. J Clin Med. 2022;11:6639.
29. Mintz GS, Guagliumi G. Intravascular imaging in coronary artery disease. Lancet. 2017;390:793-809.
30. Jang JS, Shin HC, Bae JS, et al. Diagnostic performance of intravascular ultrasound-derived minimal lumen area to predict functionally significant non-left main coronary artery disease: a meta-analysis. Korean Circ J. 2016;46:622-31.
31. Mintz GS, Matsumura M, Ali Z, Maehara A. Clinical utility of intravascular imaging: past, present, and future. JACC Cardiovasc Imaging. 2022;15:1799-820.
32. Kerensky RA, Wade M, Deedwania P, Boden WE, Pepine CJ; Veterans Affairs Non-Q-Wave Infarction Stategies in-Hospital (VANQWISH) Trial Investigators. Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol. 2002;39:1456-63.
33. Reynolds HR, Maehara A, Kwong RY, et al. Coronary optical coherence tomography and cardiac magnetic resonance imaging to determine underlying causes of myocardial infarction with nonobstructive coronary arteries in women. Circulation. 2021;143:624-40.
34. Zeng M, Zhao C, Bao X, et al. Clinical characteristics and prognosis of MINOCA caused by atherosclerotic and nonatherosclerotic mechanisms assessed by OCT. JACC Cardiovasc Imaging. 2023;16:521-32.
35. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226-35.
36. Erlinge D, Maehara A, Ben-Yehuda O, et al. Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. Lancet. 2021;397:985-95.
37. Kjøller-Hansen L, Maehara A, Kelbæk H, et al. Impact of lipidic plaque on in-stent and stent edge-related events after PCI in myocardial infarction: a PROSPECT II substudy. Circ Cardiovasc Interv. 2024;17:e014215.
38. Kubo T, Ino Y, Mintz GS, et al. Optical coherence tomography detection of vulnerable plaques at high risk of developing acute coronary syndrome. Eur Heart J Cardiovasc Imaging. 2021;22:1376-84.
39. Kedhi E, Berta B, Roleder T, et al. Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial. Eur Heart J. 2021;42:4671-9.
40. Fabris E, Berta B, Hommels T, et al. Long-term outcomes of patients with normal fractional flow reserve and thin-cap fibroatheroma. EuroIntervention. 2023;18:e1099-107.
41. Mol JQ, Volleberg RHJA, Belkacemi A, et al. Fractional flow reserve-negative high-risk plaques and clinical outcomes after myocardial infarction. JAMA Cardiol. 2023;8:1013-21.
42. Stone GW, Christiansen EH, Ali ZA, et al. Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis. Lancet. 2024;403:824-37.
43. Groenland FTW, Neleman T, Ziedses des Plantes AC, et al. Fractional flow reserve directed percutaneous coronary intervention optimization using high-definition intravascular ultrasound in non-ST-segment elevation acute coronary syndrome versus chronic coronary syndrome. Catheter Cardiovasc Interv. 2025;106:12-22.
44. Antonsen L, Thayssen P, Maehara A, et al. Optical coherence tomography guided percutaneous coronary intervention with nobori stent implantation in patients with non-ST-segment-elevation myocardial infarction (OCTACS) trial: difference in strut coverage and dynamic malapposition patterns at 6 months. Circ Cardiovasc Interv. 2015;8:e002446.
45. Kala P, Cervinka P, Jakl M, et al. OCT guidance during stent implantation in primary PCI: A randomized multicenter study with nine months of optical coherence tomography follow-up. Int J Cardiol. 2018;250:98-103.
46. Meneveau N, Souteyrand G, Motreff P, et al. Optical coherence tomography to optimize results of percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndrome: results of the multicenter, randomized DOCTORS study (does optical coherence tomography optimize results of stenting). Circulation. 2016;134:906-17.
47. Maluenda G, Lemesle G, Ben-Dor I, et al. Impact of intravascular ultrasound guidance in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2010;75:86-92.
48. Okura H, Saito Y, Soeda T, et al. Frequency and prognostic impact of intravascular imaging-guided urgent percutaneous coronary intervention in patients with acute myocardial infarction: results from J-MINUET. Heart Vessels. 2019;34:564-71.
49. Kim Y, Bae S, Johnson TW, et al. Role of intravascular ultrasound-guided percutaneous coronary intervention in optimizing outcomes in acute myocardial infarction. J Am Heart Assoc. 2022;11:e023481.
50. Yamashita T, Sakamoto K, Tabata N, et al. Imaging-guided PCI for event suppression in Japanese acute coronary syndrome patients: community-based observational cohort registry. Cardiovasc Interv Ther. 2021;36:81-90.
51. Li X, Ge Z, Kan J, et al. Intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention in acute coronary syndromes (IVUS-ACS): a two-stage, multicentre, randomised trial. Lancet. 2024;403:1855-65.
52. Otake H, Kubo T, Hibi K, et al. Optical frequency domain imaging-guided versus intravascular ultrasound-guided percutaneous coronary intervention for acute coronary syndromes: the OPINION ACS randomised trial. EuroIntervention. 2024;20:e1086-97.
53. Nakajima A, Sugiyama T, Araki M, et al. Plaque rupture, compared with plaque erosion, is associated with a higher level of pancoronary inflammation. JACC Cardiovasc Imaging. 2022;15:828-39.
54. Jia H, Dai J, Hou J, et al. Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion (the EROSION study). Eur Heart J. 2017;38:792-800.
55. Xing L, Yamamoto E, Sugiyama T, et al. EROSION study (effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion): a 1-year follow-up report. Circ Cardiovasc Interv. 2017;10:e005860.
56. He L, Qin Y, Xu Y, et al. Predictors of non-stenting strategy for acute coronary syndrome caused by plaque erosion: four-year outcomes of the EROSION study. EuroIntervention. 2021;17:497-505.
57. Park SJ, Ahn JM, Kang DY, et al. Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial. Lancet. 2024;403:1753-65.
58. Musto C, Scappaticci M, Biondi-Zoccai G, et al. Instantaneous wave-free ratio-guided revascularization of nonculprit lesions in STEMI patients with multivessel coronary disease: the WAVE registry. Catheter Cardiovasc Interv. 2022;100:351-9.
59. Bär S, Kavaliauskaite R, Ueki Y, et al. Quantitative flow ratio to predict nontarget vessel-related events at 5 years in patients with ST-segment-elevation myocardial infarction undergoing angiography-guided revascularization. J Am Heart Assoc. 2021;10:e019052.
60. Lauri FM, Macaya F, Mejía-Rentería H, et al. Angiography-derived functional assessment of non-culprit coronary stenoses in primary percutaneous coronary intervention. EuroIntervention. 2020;15:e1594-601.
61. Erriquez A, Campo G, Guiducci V, et al. QFR for the revascularization of nonculprit vessels in MI patients: insights from the FIRE trial. JACC Cardiovasc Interv. 2024;17:1425-36.
62. Erbay A, Penzel L, Abdelwahed YS, et al. Prognostic impact of quantitative flow ratio (QFR)-consistent complete revascularization in patients with myocardial infarction and multivessel coronary artery disease. Am Heart J. 2024;276:22-30.
63. Barauskas M, Žiubrytė G, Jodka N, Unikas R. Quantitative flow ratio vs. angiography-only guided PCI in STEMI patients: one-year cardiovascular outcomes. BMC Cardiovasc Disord. 2023;23:136.
64. Xu X, Fang C, Jiang S, et al. Functional or anatomical assessment of non-culprit lesions in acute myocardial infarction. EuroIntervention. 2025;21:e217-28.
